ELTXElicio Therapeutics Inc

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Elicio Therapeutics, Inc. (Elicio or the Company) (NASDAQ: ELTX) for violations of the securities laws.The investigation focuses on whether the Company issued...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX PR Newswire NEW YORK, June 25, 2026 NEW YORK, June 25, 2026...

The biotechnology space is delivering a steady stream of potentially market-moving developments this week as companies across oncology, neuroscience, gene therapy, medical devices, and synthetic biology delivered significant regulatory, clinical, and commercial updates. $NTHI, $QURE, $ICCM, $CLPT, $ELTX, $AZTR

Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX) Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX) PR Newswire NEW YORK, June 16, 2026 Elicio...

Elicio Therapeutics said the randomized trial, called AMPLIFY-7P, of its experimental immunotherapy did not achieve the pre-specified primary endpoint in certain pancreatic cancer patients.

Elicio Therapeutics (NASDAQ:ELTX) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-elicio-therapeutics-inc-stock...

LADENBURG THALM/SH SH assumed coverage on Elicio Therapeutics in a research report on Wednesday. They set a "buy" rating and a $20.00 price target for the company...

Elicio Therapeutics (NASDAQ:ELTX) Trading 1.6% Higher - Should You Buy...

Here is how Aura Biosciences, Inc. (AURA) and Elicio Therapeutics (ELTX) have performed compared to their sector so far this year.